Antiviral Approaches for the Treatment of Herpes Simplex Virus Infections in Newborn Infants

Literature Cited

1. 1.  Whitley RJ, Roizman B 2017. Herpes simplex viruses. Clinical Virology DD Richman, RJ Whitley, FG Hayden 415–45 Washington, DC: ASM Press. , 4th ed..
   [Google Scholar]
2. 2.  Roizman B, Whitley RJ 2013. An inquiry into the molecular basis of HSV latency and reactivation. Annu. Rev. Microbiol. 67:355–74
   [Google Scholar]
3. 3.  Roizman B 2011. The checkpoints of viral gene expression in productive and latent infection: the role of the HDAC/CoREST/LSD1/REST repressor complex. J. Virol. 85:7474–82
   [Google Scholar]
4. 4.  Du T, Zhou G, Roizman B 2013. Modulation of reactivation of latent herpes simplex virus 1 in ganglionic organ cultures by p300/CBP and STAT3. PNAS 110:E2621–28
   [Google Scholar]
5. 5.  Kimberlin DW 2004. Neonatal herpes simplex infection. Clin. Microbiol. Rev. 17:1–13
   [Google Scholar]
6. 6.  Stevens JG, Cook ML 1971. Latent herpes simplex virus in spinal ganglia of mice. Science 173:843–45
   [Google Scholar]
7. 7.  Subak-Sharpe JH, Dargan DJ 1998. HSV molecular biology: general aspects of herpes simplex virus molecular biology. Virus Genes 16:239–51
   [Google Scholar]
8. 8.  Heilingloh CS, Krawczyk A 2017. Role of L-particles during herpes simplex virus infection. Front. Microbiol. 8:2565
   [Google Scholar]
9. 9.  Campbell MEM, Palfreyman JW, Preston CM 1984. Identification of herpes simplex virus DNA sequences which encode a trans-acting polypeptide responsible for stimulation of immediate early transcription. J. Mol. Biol. 180:1–19
   [Google Scholar]
10. 10.  Preston CM, Frame MC, Campbell MEM 1988. A complex formed between cell components and an HSV structural polypeptide binds to a viral immediate early gene regulatory DNA sequence. Cell 52:425–34
    [Google Scholar]
11. 11.  Gaffney DF, McLaughlan J, Whitton JL, Clements JB 1985. A novel transcription property of SP6 and T7 RNA polymerases: dependence on template structure. Nucleic Acids Res 13:7847–63
    [Google Scholar]
12. 12.  Ward S, Weller S 2011. HSV-1 DNA replication. Alphaherpesviruses: Molecular Virology SK Weller 89–112 Norfolk, UK: Caister Acad
    [Google Scholar]
13. 13.  Liu S, Knafels JD, Chang JS, Waszak GA, Baldwin ET et al. 2006. Crystal structure of the herpes simplex virus 1 DNA polymerase. J. Biol. Chem. 281:18193–200
    [Google Scholar]
14. 14.  Bogani F, Boehmer PE 2008. The replicative DNA polymerase of herpes simplex virus 1 exhibits apurinic/apyrimidinic and 5′-deoxyribose phosphate lyase activities. PNAS 105:11709–14
    [Google Scholar]
15. 15.  Jiang C, Komazin-Meredith G, Tian W, Coen DM, Hwang CBC 2009. Mutations that increase DNA binding by the processivity factor of herpes simplex virus affect virus production and DNA replication fidelity. J. Virol. 83:7573–80
    [Google Scholar]
16. 16.  Chattopadhyay S, Chen Y, Weller SK 2006. The two helicases of herpes simplex virus type 1 (HSV-1). Front. Biosci. 11:2213–23
    [Google Scholar]
17. 17.  Weller SK, Coen DM 2012. Herpes simplex viruses: mechanism of DNA replication. Cold Spring Harb. Perspect. Biol. 4:a013011
    [Google Scholar]
18. 18.  Ashley RL 1998. Genital herpes. Type-specific antibodies for diagnosis and management. Dermatol. Clin. 16:789–93
    [Google Scholar]
19. 19.  Smith JS, Robinson NJ 2002. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J. Infect. Dis. 186:Suppl. 1S3–28
    [Google Scholar]
20. 20.  Whitley RJ 1990. Herpes simplex virus infections. Infectious Diseases of the Fetus and Newborn Infants JS Remington, JO Klein 282–305 Philadelphia: Saunders
    [Google Scholar]
21. 21.  Kulhanjian JA, Soroush V, Au DS, Bronzan RN, Yasukawa LL et al. 1992. Identification of women at unsuspected risk of primary infection with herpes simplex virus type 2 during pregnancy. N. Engl. J. Med. 326:916–20
    [Google Scholar]
22. 22.  Kucera P, Gerber S, Marques-Vidal P, Meylan PR 2012. Seroepidemiology of herpes simplex virus type 1 and 2 in pregnant women in Switzerland: an obstetric clinic based study. Eur. J. Obstet. Gynecol. Reprod. Biol. 160:13–17
    [Google Scholar]
23. 23.  Kimberlin DW, Brady MT, Jackson MA, Long SS 2015. Red Book: 2015 Report of the Committee on Infectious Diseases Elk Grove Village, IL: Am. Acad. Pediatr. , 30th ed..
24. 24.  Brown ZA, Selke S, Zeh J, Kopelman J, Maslow A et al. 1997. The acquisition of herpes simplex virus during pregnancy. N. Engl. J. Med. 337:509–15
    [Google Scholar]
25. 25.  Whitley RJ, Corey L, Arvin A, Lakeman FD, Sumaya CV et al. 1988. Changing presentation of herpes simplex virus infection in neonates. J. Infect. Dis. 158:109–16
    [Google Scholar]
26. 26.  Whitley RJ, Nahmias AJ, Visintine AM, Fleming CL, Alford CA 1980. The natural history of herpes simplex virus infection of mother and newborn. Pediatrics 66:489–94
    [Google Scholar]
27. 27.  Yeager AS, Arvin AM 1984. Reasons for the absence of a history of recurrent genital infections in mothers of neonates infected with herpes simplex virus. Pediatrics 73:188–93
    [Google Scholar]
28. 28.  Sullender WM, Yasukawa LL, Schwartz M, Pereira L, Hensleigh PA et al. 1988. Type-specific antibodies to herpes simplex virus type 2 (HSV-2) glycoprotein G in pregnant women, infants exposed to maternal HSV-2 infection at delivery, and infants with neonatal herpes. J. Infect. Dis. 157:164–71
    [Google Scholar]
29. 29.  Corey L, Wald A 2009. Maternal and neonatal herpes simplex virus infections. N. Engl. J. Med. 361:1376–85
    [Google Scholar]
30. 30. ACOG (Am. Coll. Obstet. Gynecol.) Comm. Pract. Bull. 2007. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. No. 82 June 2007. Management of herpes in pregnancy Obstet. Gynecol 109:1489–98
    [Google Scholar]
31. 31.  Watts DH, Brown ZA, Money D, Selke S, Huang ML et al. 2003. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. Am. J. Obstet. Gynecol. 188:836–43
    [Google Scholar]
32. 32.  Andrews WW, Kimberlin DF, Whitley R, Cliver S, Ramsey PS, Deeter R 2006. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. Am. J. Obstet. Gynecol. 194:774–81
    [Google Scholar]
33. 33.  Lafferty WE, Downey L, Celum C, Wald A 2000. Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J. Infect. Dis. 181:1454–57
    [Google Scholar]
34. 34.  Flagg EW, Weinstock H 2011. Incidence of neonatal herpes simplex virus infections in the United States, 2006. Pediatrics 127:e1–8
    [Google Scholar]
35. 35.  Handel S, Klingler EJ, Washburn K, Blank S, Schillinger JA 2011. Population-based surveillance for neonatal herpes in New York City, April 2006-September 2010. Sex. Transm. Dis. 38:705–11
    [Google Scholar]
36. 36.  Whitley R, Davis EA, Suppapanya N 2007. Incidence of neonatal herpes simplex virus infections in a managed-care population. Sex. Transm. Dis. 34:704–8
    [Google Scholar]
37. 37.  Shah SS, Hall M, Schondelmeyer AC, Berry JG, Kimberlin DW, Mahant S 2017. Trends in neonatal herpes simplex virus infection in the United States, 2000–2012 Paper presented at Pediatric Hospital Medicine 2017 Nashville, TN: July 20–23
38. 38. CDC (Cent. Dis. Contr. Prev.). 2016. Sexually transmitted diseases surveillance: STDs in women and infants Rep., Cent. Dis. Contr. Prev Atlanta, GA: https://www.cdc.gov/std/stats15/womenandinf.htm
39. 39. CDC (Cent. Dis. Contr. Prev.). 2016. Monitoring selected national HIV prevention and care objectives by using HIV-surveillance data—United States and 6 dependent areas, 2014 HIV Surveill. Suppl. Rep. 21 No. 4, Cent Dis. Contr. Prev Atlanta, GA: https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-21-4.pdf
40. 40. CDC (Cent. Dis. Contr. Prev.). 2016. Clinical overview: Group B strep Rep., Cent. Dis. Contr. Prev Atlanta, GA: https://www.cdc.gov/groupbstrep/clinicians/clinical-overview.html
41. 41. CDC (Cent. Dis. Contr. Prev.). 2017. Surveillance for viral hepatitis—United States, 2015 Rep., Cent. Dis. Contr Prev., Atlanta, GA: https://www.cdc.gov/hepatitis/statistics/2015surveillance/index.htm
42. 42.  Baldwin S, Whitley RJ 1989. Intrauterine herpes simplex virus infection. Teratology 39:1–10
    [Google Scholar]
43. 43.  Florman AL, Gershon AA, Blackett PR, Nahmias AJ 1973. Intrauterine infection with herpes simplex virus. Resultant congenital malformations. JAMA 225:129–32
    [Google Scholar]
44. 44.  Hutto C, Arvin A, Jacobs R, Steele R, Stagno S et al. 1987. Intrauterine herpes simplex virus infections. J. Pediatr. 110:97–101
    [Google Scholar]
45. 45.  Kimberlin DW 2005. Herpes simplex virus infections in neonates and early childhood. Semin. Pediatr. Infect. Dis. 16:271–81
    [Google Scholar]
46. 46.  Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Frenkel LM et al. 2001. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 108:223–29
    [Google Scholar]
47. 47.  Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Corey L et al. 2001. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 108:230–38
    [Google Scholar]
48. 48.  Kimberlin DW, Lakeman FD, Arvin AM, Prober CG, Corey L et al. 1996. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. J. Infect. Dis. 174:1162–67
    [Google Scholar]
49. 49.  Malm G, Forsgren M 1999. Neonatal herpes simplex virus infections: HSV DNA in cerebrospinal fluid and serum. Arch. Dis. Child. Fetal Neonatal Ed. 81:F24–29
    [Google Scholar]
50. 50.  Kimura H, Futamura M, Kito H, Ando T, Goto M et al. 1991. Detection of viral DNA in neonatal herpes simplex virus infections: frequent and prolonged presence in serum and cerebrospinal fluid. J. Infect. Dis. 164:289–93
    [Google Scholar]
51. 51.  Troendle-Atkins J, Demmler GJ, Buffone GJ 1993. Rapid diagnosis of herpes simplex virus encephalitis by using the polymerase chain reaction. J. Pediatr. 123:376–80
    [Google Scholar]
52. 52.  Mejias A, Bustos R, Ardura MI, Ramirez C, Sanchez PJ 2009. Persistence of herpes simplex virus DNA in cerebrospinal fluid of neonates with herpes simplex virus encephalitis. J. Perinatol. 29:290–96
    [Google Scholar]
53. 53.  Otto WR, Myers AL, LaRussa B, Kimberlin DW, Jackson MA 2017. Clinical markers and outcomes of neonates with herpes simplex virus deoxyribonucleic acid persistence in cerebrospinal fluid in disseminated and central nervous system infection. J. Pediatr. Infect. Dis. Soc. 7:e30–33
    [Google Scholar]
54. 54.  Cantey JB, Mejias A, Wallihan R, Doern C, Brock E et al. 2012. Use of blood polymerase chain reaction testing for diagnosis of herpes simplex virus infection. J. Pediatr. 161:357–61
    [Google Scholar]
55. 55.  Melvin AJ, Mohan KM, Schiffer JT, Drolette LM, Magaret A et al. 2015. Plasma and cerebrospinal fluid herpes simplex virus levels at diagnosis and outcome of neonatal infection. J. Pediatr. 166:827–33
    [Google Scholar]
56. 56.  James SH, Kimberlin DW 2015. Quantitative herpes simplex virus concentrations in neonatal infection. J. Pediatr. 166:793–95
    [Google Scholar]
57. 57.  Kaufman HE 1962. Clinical cure of herpes simplex keratitis by 5-iodo-2′deoxyuridine. Proc. Soc. Exp. Biol. Med. 109:251–52
    [Google Scholar]
58. 58.  Boston Interhosp. Virus Study Group, Natl. Inst. Allergy Infect. Dis. (NIAID)-Spons. Coop. Antivir. Clin. Study. 1975. Failure of high dose 5-iodo-2′-deoxyuridine in the therapy of herpes simplex virus encephalitis—evidence of unacceptable toxicity. N. Engl. J. Med 292:599–603
    [Google Scholar]
59. 59.  Cleary JM, Rosen LS, Yoshida K, Rasco D, Shapiro GI, Sun W 2017. A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) versus trifluridine alone. Investig. New Drugs 35:189–97
    [Google Scholar]
60. 60.  Wellings PC, Awdry PN, Bors FH, Jones BR, Brown DC, Kaufman HE 1972. Clinical evaluation of trifluorothymidine in the treatment of herpes simplex corneal ulcers. Am. J. Ophthalmol. 73:932–42
    [Google Scholar]
61. 61.  Pavan-Langston D, Dohlman CH 1972. A double blind clinical study of adenine arabinoside therapy of viral keratoconjunctivitis. Am. J. Ophthalmol. 74:81–88
    [Google Scholar]
62. 62.  van Bijsterveld OP, Post H 1980. Trifluorothymidine versus adenine arabinoside in the treatment of herpes simplex keratitis. Br. J. Ophthalmol. 64:33–36
    [Google Scholar]
63. 63.  Whitley RJ, Nahmias AJ, Soong SJ, Galasso GG, Fleming CL, Alford CA 1980. Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics 66:495–501
    [Google Scholar]
64. 64.  Whitley RJ, Yeager A, Kartus P, Bryson Y, Connor JD et al. 1983. Neonatal herpes simplex virus infection: follow-up evaluation of vidarabine therapy. Pediatrics 72:778–85
    [Google Scholar]
65. 65.  Whitley RJ, Soong SJ, Dolin R, Galasso GJ, Ch'ien LT, Alford CA 1977. Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis—National Institute of Allergy and Infectious Diseases collaborative antiviral study. N. Engl. J. Med. 297:289–94
    [Google Scholar]
66. 66.  Whitley RJ, Ch'ien LT, Dolin R, Galasso GJ, Alford CA Jr 1976. Adenine arabinoside therapy of herpes zoster in the immunosuppressed: NIAID collaborative antiviral study. N. Engl. J. Med. 294:1193–99
    [Google Scholar]
67. 67.  Whitley RJ, Soong SJ, Dolin R, Betts R, Linnemann C Jr, Alford CA Jr 1982. Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. N. Engl. J. Med. 307:971–75
    [Google Scholar]
68. 68.  King DH 1988. History, pharmacokinetics, and pharmacology of acyclovir. J. Am. Acad. Dermatol. 18:176–79
    [Google Scholar]
69. 69.  Whitley R, Arvin A, Prober C, Burchett S, Corey L et al. 1991. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. N. Engl. J. Med. 324:444–49
    [Google Scholar]
70. 70.  Kimberlin DW, Whitley RJ, Wan W, Powell DA, Storch G et al. 2011. Oral acyclovir suppression and neurodevelopment after neonatal herpes. N. Engl. J. Med. 365:1284–92
    [Google Scholar]
71. 71.  Elion GB 1982. Mechanism of action and selectivity of acyclovir. Am. J. Med. 73:7–13
    [Google Scholar]
72. 72.  Wagstaff AJ, Faulds D, Goa KL 1994. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47:153–205
    [Google Scholar]
73. 73.  Lai L, Xu Z, Zhou J, Lee KD, Amidon GL 2008. Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J. Biol. Chem. 283:9318–27
    [Google Scholar]
74. 74.  Perry CM, Faulds D 1996. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 52:754–72
    [Google Scholar]
75. 75.  Kimberlin DW, Jacobs RF, Weller S, van der Walt JS, Heitman CK et al. 2010. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age. Clin. Infect. Dis. 50:221–28
    [Google Scholar]
76. 76.  Piret J, Boivin G 2011. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob. Agents Chemother. 55:459–72
    [Google Scholar]
77. 77.  Nyquist AC, Rotbart HA, Cotton M, Robinson C, Weinberg A et al. 1994. Acyclovir-resistant neonatal herpes simplex virus infection of the larynx. J. Pediatr. 124:967–71
    [Google Scholar]
78. 78.  Bache M, Andrei G, Bindl L, Bofferding L, Bottu J et al. 2014. Antiviral drug-resistance typing reveals compartmentalization and dynamics of acyclovir-resistant herpes simplex virus type-2 (HSV-2) in a case of neonatal herpes. J. Pediatr. Infect. Dis. Soc. 3:e24–27
    [Google Scholar]
79. 79.  Pinninti SG, Angara R, Feja KN, Kimberlin DW, Leach CT et al. 2012. Neonatal herpes disease following maternal antenatal antiviral suppressive therapy: a multicenter case series. J. Pediatr. 161:134–38
    [Google Scholar]
80. 80.  Crumpacker CS 1992. Mechanism of action of foscarnet against viral polymerases. Am. J. Med. 92:S3–7
    [Google Scholar]
81. 81.  Wang Y, Smith KP 2014. Safety of alternate antiviral agents for neonatal herpes simplex virus encephalitis and disseminated infection. J. Pediatr. Pharmacol. Ther. 19:72–82
    [Google Scholar]
82. 82.  Prober CG, Sullender WM, Yasukawa LL, Au DS, Yeager AS, Arvin AM 1987. Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections. N. Engl. J. Med. 316:240–44
    [Google Scholar]
83. 83.  Sullender WM, Miller JL, Yasukawa LL, Bradley JS, Black SB et al. 1987. Humoral and cell-mediated immunity in neonates with herpes simplex virus infection. J. Infect. Dis. 155:28–37
    [Google Scholar]
84. 84.  Kohl S, West MS, Prober CG, Sullender WM, Loo LS, Arvin AM 1989. Neonatal antibody-dependent cellular cytotoxic antibody levels are associated with the clinical presentation of neonatal herpes simplex virus infection. J. Infect. Dis. 160:770–76
    [Google Scholar]
85. 85.  Kohl S, Strynadka NC, Hodges RS, Pereira L 1990. Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B. J. Clin. Investig. 86:273–78
    [Google Scholar]
86. 86.  Bravo FJ, Bourne N, Harrison CJ, Mani C, Stanberry LR et al. 1996. Effect of antibody alone and combined with acyclovir on neonatal herpes simplex virus infection in guinea pigs. J. Infect. Dis. 173:1–6
    [Google Scholar]
87. 87.  Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L 2003. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 289:203–9
    [Google Scholar]
88. 88.  Nahmias AJ, Josey WE, Naib ZM, Freeman MG, Fernandez RJ, Wheeler JH 1971. Perinatal risk associated with maternal genital herpes simplex virus infection. Am. J. Obstet. Gynecol. 110:825–37
    [Google Scholar]
89. 89. ACOG (Am. Coll. Obstet. Gynecol.) Comm. Pract. Bull. 2000. ACOG practice bulletin. Management of herpes in pregnancy. No. 8 October 1999. Clinical management guidelines for obstetrician-gynecologists. Int. J. Gynaecol. Obstet 68:165–73
    [Google Scholar]
90. 90.  Randolph AG, Washington AE, Prober CG 1993. Cesarean delivery for women presenting with genital herpes lesions: efficacy, risks, and costs. JAMA 270:77–82
    [Google Scholar]
91. 91.  Randolph AG, Hartshorn RM, Washington AE 1996. Acyclovir prophylaxis in late pregnancy to prevent neonatal herpes: a cost-effectiveness analysis. Obstet. Gynecol. 88:603–10
    [Google Scholar]
92. 92.  Reiff-Eldridge R, Heffner CR, Ephross SA, Tennis PS, White AD, Andrews EB 2000. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am. J. Obstet. Gynecol. 182:159–63
    [Google Scholar]
93. 93.  Braig S, Luton D, Sibony O, Edlinger C, Boissinot C et al. 2001. Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding. Eur. J. Obstet. Gynecol. Reprod. Biol. 96:55–58
    [Google Scholar]
94. 94.  Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD Jr 1996. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstet. Gynecol. 87:69–73
    [Google Scholar]
95. 95.  Stray-Pedersen B 1990. Acyclovir in late pregnancy to prevent neonatal herpes simplex. Lancet 336:756
    [Google Scholar]
96. 96.  Brocklehurst P, Kinghorn G, Carney O, Helsen K, Ross E et al. 1998. A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection. Br. J. Obstet. Gynaecol. 105:275–80
    [Google Scholar]
97. 97.  Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ et al. 2012. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 366:34–43
    [Google Scholar]
98. 98.  Awasthi S, Hook LM, Shaw CE, Friedman HM 2017. A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model. Hum. Vaccin. Immunother. 13:2785–93
    [Google Scholar]
99. 99.  Crumpacker CS, Schaffer PA 2002. New anti-HSV therapeutics target the helicase-primase complex. Nat. Med. 8:327–28
    [Google Scholar]
100. 100.  Birkmann A, Zimmermann H 2016. HSV antivirals—current and future treatment options. Curr. Opin. Virol. 18:9–13
     [Google Scholar]
101. 101. Am. Acad. Pediatr. 2018. Red Book Online Itasca, IL: Am. Acad. Pediatr